Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Background Recent studies have reported the effects of metabolic syndrome (MetS) and its
components on atrial fibrillation (AF), but the results remain controversial. Therefore, we …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background Individuals with diabetes have a high risk of cardiovascular disease (CVD).
However, the association between type 1 diabetes mellitus (T1DM) and the risk of CVD has …

Risk assessments are an important element in the management of patients with atrial
fibrillation (AF). In this review, we aim to discuss the concepts and controversies surrounding …

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …